Free Trial

Wellington Management Group LLP Invests $775,000 in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)

Mineralys Therapeutics logo with Medical background

Wellington Management Group LLP bought a new position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor bought 63,998 shares of the company's stock, valued at approximately $775,000. Wellington Management Group LLP owned 0.13% of Mineralys Therapeutics at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. SG Americas Securities LLC purchased a new stake in shares of Mineralys Therapeutics in the third quarter worth $110,000. China Universal Asset Management Co. Ltd. grew its position in Mineralys Therapeutics by 64.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,564 shares of the company's stock valued at $116,000 after purchasing an additional 3,732 shares during the last quarter. Federated Hermes Inc. increased its stake in Mineralys Therapeutics by 100.0% during the 2nd quarter. Federated Hermes Inc. now owns 12,000 shares of the company's stock valued at $140,000 after purchasing an additional 6,000 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new position in Mineralys Therapeutics in the second quarter worth about $145,000. Finally, PDT Partners LLC bought a new position in shares of Mineralys Therapeutics in the third quarter worth approximately $148,000. 84.46% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a "buy" rating and set a $30.00 price target on shares of Mineralys Therapeutics in a report on Tuesday, November 12th.

View Our Latest Stock Report on MLYS

Mineralys Therapeutics Price Performance

Shares of Mineralys Therapeutics stock traded up $0.51 during trading on Friday, hitting $12.34. 512,659 shares of the company's stock traded hands, compared to its average volume of 179,117. Mineralys Therapeutics, Inc. has a 1 year low of $7.29 and a 1 year high of $16.91. The business has a 50-day simple moving average of $13.12 and a 200-day simple moving average of $12.57. The stock has a market capitalization of $614.15 million, a P/E ratio of -3.77 and a beta of 1.55.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last released its quarterly earnings results on Monday, November 11th. The company reported ($1.13) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.30). During the same quarter in the previous year, the company earned ($0.57) earnings per share. On average, equities analysts predict that Mineralys Therapeutics, Inc. will post -3.63 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider David Malcom Rodman sold 25,482 shares of the business's stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $15.03, for a total value of $382,994.46. Following the sale, the insider now directly owns 135,974 shares in the company, valued at $2,043,689.22. The trade was a 15.78 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Jon Congleton sold 15,271 shares of the firm's stock in a transaction that occurred on Friday, October 11th. The shares were sold at an average price of $13.52, for a total value of $206,463.92. Following the completion of the sale, the chief executive officer now directly owns 895,941 shares of the company's stock, valued at $12,113,122.32. The trade was a 1.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 51,510 shares of company stock valued at $735,431. 33.24% of the stock is owned by corporate insiders.

Mineralys Therapeutics Profile

(Free Report)

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.

Recommended Stories

Institutional Ownership by Quarter for Mineralys Therapeutics (NASDAQ:MLYS)

Should you invest $1,000 in Mineralys Therapeutics right now?

Before you consider Mineralys Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mineralys Therapeutics wasn't on the list.

While Mineralys Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

The Real Reason Tesla Stock Is Soaring – and Why Tech Expert Says It Won’t Stop

The Real Reason Tesla Stock Is Soaring – and Why Tech Expert Says It Won’t Stop

Join tech expert Jeff Brown, the founder of Brownstone Research, as he breaks down what’s driving Tesla's latest rally and how AI is fueling future growth.

Related Videos

Why Meta Is Still a Top Stock Pick for 2025
Why Amazon’s AI Power and Holiday Boost Make This Stock a 2025 Winner
Small Caps, Financials & Bitcoin Lead the Rising Bull Market: Chris Rowe’s Top Picks

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines